Measures · D03 in 2018 · Part D · DD1 Drug Plan Customer Service
Appeals Upheld
AppealsDrug PlanSource: Independent Review Entity
- What it measures
- How often an Independent Reviewer thought the drug plan’s decision to deny an appeal was fair. This includes appeals made by plan members and out-of-network providers. (This rating is not based on how often the plan denies appeals, but rather how fair the plan is when they do deny an appeal.)
- How it's calculated
- This measure is defined as the percent of IRE confirmations of upholding the plans’ decisions. This is calculated as: [(Number of cases upheld) / (Total number of cases reviewed)] * 100. Total number of cases reviewed is defined all cases received by the IRE during the timeframe and receiving a decision before May 1, 2017. The denominator is equal to the number of cases upheld, fully reversed, and partially reversed. Dismissed, remanded, and withdrawn cases are not included in the denominator. Auto-forwarded cases are included, as these are considered to be adverse decisions per Subpart M rules. If a Reopening occurs and is decided prior to May 1, 2017, the Reopened decision is used in place of the Reconsideration decision. Reopenings decided on or after May 1, 2017 are not reflected in these data, the original decision result is used. The results of appeals that occur beyond Level 2 (i.e., Administrative Law Judge or Medicare Appeals Council appeals) are not included in the data. Contracts with no IRE cases reviewed will not receive a score in this measure.
- Data source
- Independent Review Entity (IRE) Data were obtained from the Independent Review Entity (IRE) contracted by CMS for Part D reconsiderations. The appeals used in this measure are based on the date they were received by the IRE, not the date a decision was reached by the IRE.
- Measurement period
- 01/01/2016 – 12/31/2016
- Better when
- Higher
- Weight
- 1.5 (Measures Capturing Access)
- Star assignment
- Clustering
- Case-mix adjusted
- —
- In improvement measure
- Yes
- Used in CAI
- No
- Exclusions
Show
Contracts with fewer than 10 cases reviewed by the IRE.
From the 2018 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts.
2018 star distribution
Not rated: Not enough data available (304); Plan too new to be measured (85); Plan not required to report measure (15); No data available (7)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2021 | MA-PD | < 79 % | >= 79 % to < 85 % | >= 85 % to < 89 % | >= 89 % to < 95 % | >= 95 % |
| 2021 | PDP | < 80 % | >= 80 % to < 87 % | >= 87 % to < 93 % | >= 93 % to < 97 % | >= 97 % |
| 2020 | MA-PD | < 71% | ? 71% to < 78% | ? 78% to < 86% | ? 86% to < 94% | ? 94% |
| 2020 | PDP | < 80% | ? 80% to < 84% | ? 84% to < 90% | ? 90% to < 94% | ? 94% |
| 2019 | MA-PD | < 60% | ? 60% to < 69% | ? 69% to < 81% | ? 81% to < 92% | ? 92% |
| 2019 | PDP | < 64% | ? 64% to < 78% | ? 78% to < 89% | ? 89% to < 91% | ? 91% |
| 2018 | MA-PD | < 56% | ? 56% to < 71% | ? 71% to < 79% | ? 79% to < 89% | ? 89% |
| 2018 | PDP | < 61% | ? 61% to < 71% | ? 71% to < 81% | ? 81% to < 92% | ? 92% |
| 2017 | MA-PD | < 47% | ? 47% to < 66% | ? 66% to < 78% | ? 78% to < 88% | ? 88% |
| 2017 | PDP | < 60% | ? 60% to < 66% | ? 66% to < 77% | ? 77% to < 91% | ? 91% |
| 2016 | MA-PD | < 42% | ? 42% to < 60% | ? 60% to < 73% | ? 73% to < 88% | ? 88% |
| 2016 | PDP | < 54% | ? 54% to < 65% | ? 65% to < 76% | ? 76% to < 91% | ? 91% |
| 2015 | MA-PD | < 50% | ? 50% to < 60% | ? 60% to < 72% | ? 72% to < 84% | ? 84% |
| 2015 | PDP | < 48% | ? 48% to < 58% | ? 58% to < 68% | ? 68% to < 78% | ? 78% |
Lowest-scoring contracts, 2018
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| S0655 Tufts Health Plan | Point32Health, Inc. | — | 61 | 2 | — | 20 | 0% |
| E0654 TEAMStar Medicare Part D Prescription Drug Program | IBT Voluntary Employee Benefits Trust | — | 43 | 1 | −3 | 36 | 0% |
| H2174 Wellcare | Centene Corporation | 4,693 | 45 | 1 | — | 34 | 1% |
| H3954 Geisinger Gold | Risant Health, Inc. | 71,757 | 49 | 1 | −1 | 30 | 1% |
| H5050 Kaiser Permanente | Kaiser Foundation Health Plan, Inc. | 99,167 | 56 | 2 | −3 | 23 | 2% |
| H5141 Clover Health | Clover Health Holdings, Inc. | 156,154 | 59 | 2 | — | 20 | 2% |
| H3864 PacificSource Medicare | PacificSource | 52,292 | 59 | 2 | −2 | 20 | 2% |
| S8841 Optum Insurance of Ohio, Inc. | UnitedHealth Group, Inc. | 1,022,627 | 67 | 2 | −1 | 14 | 3% |
| S4607 Merit Health Insurance Company | Magellan Health, Inc. | — | 67 | 2 | — | 14 | 3% |
| S3875 Granite Alliance | Prime Therapeutics, LLC. | 0 | 67 | 2 | −1 | 14 | 3% |
| H4875 Priority Health Medicare | Corewell Health | 113,078 | 63 | 2 | — | 16 | 3% |
| H7220 Anthem HealthKeepers | Elevance Health, Inc. | 10,824 | 64 | 2 | −1 | 15 | 4% |
| H3924 Geisinger Gold | Risant Health, Inc. | 24,445 | 64 | 2 | 0 | 15 | 4% |
| H4882 HealthPartners | HealthPartners, Inc. | 49,016 | 64 | 2 | — | 15 | 4% |
| H2462 HealthPartners | HealthPartners, Inc. | 2,822 | 64 | 2 | — | 15 | 4% |
| H4152 Blue Cross & Blue Shield of Rhode Island | Blue Cross & Blue Shield of Rhode Island | 74,436 | 65 | 2 | — | 14 | 6% |
| H3305 MVP HEALTH CARE | MVP Health Care, Inc. | 27,158 | 65 | 2 | −3 | 14 | 6% |
| H0354 HealthSpring | Health Care Service Corporation | 75,493 | 66 | 2 | +1 | 13 | 7% |
| H3813 Moda Health Plan, Inc. | Moda Partners, Inc. | — | 67 | 2 | 0 | 12 | 8% |
| H0562 Wellcare | Centene Corporation | 23,649 | 67 | 2 | −1 | 12 | 8% |
| H7020 HealthSpring | Health Care Service Corporation | 15,661 | 67 | 2 | +1 | 12 | 8% |
| E3014 Pennsylvania Public School Employees Retirement Sy | Commonwealth of PA Pub Schools Retirement System | 95,657 | 67 | 2 | 0 | 12 | 8% |
| H9725 HealthSpring | Health Care Service Corporation | 33,438 | 68 | 2 | +1 | 11 | 10% |
| H5106 Highmark Blue Cross Blue Shield | Highmark Health | 16,043 | 68 | 2 | — | 11 | 10% |
| S9701 Navitus MedicareRx | Medica Holding Company | 102,337 | 69 | 2 | 0 | 12 | 11% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2021 | D03 | Appeals Upheld | 01/01/2019 – 12/31/2019 | 2 | Independent Review Entity |
| 2020 | D03 | Appeals Upheld | 01/01/2018– 12/31/2018 | 1.5 | Independent Review Entity |
| 2019 | D03 | Appeals Upheld | 01/01/2017 – 12/31/2017 | 1.5 | Independent Review Entity |
| 2018 | D03 | Appeals Upheld | 01/01/2016 – 12/31/2016 | 1.5 | Independent Review Entity |
| 2017 | D03 | Appeals Upheld | 01/01/2015 - 12/31/2015 | 1.5 | Independent Review Entity |
| 2016 | D03 | Appeals Upheld | 01/01/2014 - 12/31/2014 | 1.5 | Independent Review Entity |
| 2015 | D02 | Appeals Upheld | 01/01/2014 - 06/30/2014 | 1.5 | Independent Review Entity |